Pennsylvania Cannabis: 35% Capture, America's Best Medical Program, and a Legislature That Won't Finish the Job
Pennsylvania operates the most successful medical-only cannabis program in the United States — 439,381 active patients, $9.05 billion in cumulative sales, 49% retail price compression since 2021, and 35% legal capture without a single adult-use transaction. Five of six border states have legalized adult-use cannabis. The House passed legalization in May 2025. The Senate killed it six days later. The medical program isn't failing. The legislature is.
Market Overview
Pennsylvania enacted its Medical Marijuana Act in April 2016. First patient sales launched February 15, 2018. There is no adult-use program. The market is regulated by the Pennsylvania Department of Health.
Key metrics:
- 185 dispensaries statewide (30 grower/processors)
- 2025 annual sales: $1.80 billion (PA MMO transaction data)
- $7.59/g flower (pre-tax, October 2025; down from $14.90/g in January 2021)
- 1.7% effective consumer tax burden (5% wholesale gross receipts only; no retail sales tax)
- ~35% estimated legal capture
- $9.73M revenue per store annually
- 439,381 active patients; 1,086,106 program-to-date registrations
Flower Pricing
Pennsylvania's pricing data comes from mandatory monthly operator reporting to the Department of Health. At $7.59/g, Pennsylvania is priced above most mature recreational markets — but the sticker price is the consumer price. There is no retail sales tax on medical cannabis in Pennsylvania.
| Market | Pre-tax Price | Tax Burden | Final Price | Legal Capture |
|---|---|---|---|---|
| Michigan | $2.96/g | ~17% | ~$3.46 | 165% |
| Colorado | $3.18/g | 15-20% | $3.66-3.82 | 104% |
| Oregon | $3.33/g | 17-20% | $3.89-4.00 | 100% |
| Massachusetts | $4.01/g | 17-20% | $4.69-4.81 | 100% |
| New Mexico | $4.04/g | ~20-21% | ~$4.80 | 138% |
| Nevada | $5.11/g | ~27% | $6.49 | 100% |
| Maine | $6.38/g | 18.7% | $7.57 | 100% |
| Rhode Island | $5.67/g | 20% | $6.80 | 39% |
| Pennsylvania | $7.59/g | ~1.7% | $7.59 | 35% (medical only) |
| Arizona | $6-10/g | ~22% | $7-12 | ~67% |
| New Jersey | $8.09/g | 8-10% | $8.80 | 20% |
| Arkansas | $8.10/g | ~10.5% | ~$9.00 | 24% |
| Maryland | $8.28/g | 12% | $9.27 | 49% |
| New York | $10.61/g | 20-22% | $12.70 | 8% |
| Minnesota | $13.54/g | 22-25% | $16.50-16.90 | 6% |
A Pennsylvania patient pays $7.59/g with no tax. A New Jersey recreational consumer pays $8.09/g plus ~10% tax = $8.90/g. The gap is narrowing — which makes the border leakage problem somewhat less catastrophic than raw price comparison suggests, but not reversing it. No medical card is required in New Jersey.
Tax Structure
- 5% wholesale gross receipts tax applied grower/processor to dispensary
- 0% retail sales tax on medical cannabis
- Effective consumer burden: ~1.7% ($30.4M tax on $1.8B retail)
- Lowest effective consumer tax burden of any legal cannabis market in the dataset
The 5% wholesale tax embeds invisibly in retail pricing — patients don't see a tax line at checkout. The structure is not the problem. Pennsylvania's 1.7% consumer burden is competitive with any market. The problem is that 65% of demand buys from the black market or crosses into New Jersey, Maryland, Delaware, or Ohio where adult-use sales require no card.
Total Addressable Market
Pennsylvania's adult population is approximately 10.3 million. Applying the empirically validated consumption baseline of 18% participation at 1.0 gram per day:
- 10.3 million adults 21+
- 1.86 million estimated regular consumers (18%)
- 679 million grams annual demand
- TAM at $7.59/g: ~$5.15 billion
Actual 2025 legal revenue of $1.80B against the $5.15B TAM implies approximately 35% capture, with an estimated $3.35 billion flowing through unlicensed channels and border states annually. Pennsylvania's 439,381 active patients represent approximately 24% of estimated total consumers — the program reaches about one in four cannabis users through a registration-required medical framework.
Revenue Trend
| Year | Annual Sales | YoY Growth |
|---|---|---|
| 2020 | $823M | +169% |
| 2021 | $1.35B | +64% |
| 2022 | $1.46B | +8% |
| 2023 | $1.53B | +5% |
| 2024 | $1.73B | +13% |
| 2025 | $1.80B | +4% |
Seven consecutive years of positive growth from a medical-only program is the strongest sustained performance signal in the dataset. Growth is plateauing — the program has reached the natural ceiling of what a registration-required, medical-only framework can capture from a 1.86 million consumer population.
Pennsylvania vs. Florida: The Access Cost Gap
Pennsylvania (35% capture) and Florida (21% capture) are the two largest medical-only programs in the country. The 14-point gap traces almost entirely to registration cost:
| Cost Component | Pennsylvania | Florida |
|---|---|---|
| State registration fee | $50/year | $75/year |
| Physician recertification | Every 12 months | Every 7 months (~2x/year) |
| Total annual patient cost | ~$125–200 | ~$275–375 |
| Hardship fee waiver | Yes (Medicaid, SNAP, WIC, CHIP) | No state program |
Lower the friction — fewer patients, fewer transactions, lower capture. Pennsylvania's simpler access model is the primary explanation for a 14-point capture advantage over a structurally similar program.
Dispensary Density
| Market | Stores | Adults 21+ | Per 100K | Revenue/Store | Legal Capture |
|---|---|---|---|---|---|
| Massachusetts | 405 | 5.6M | 7.2 | $4.07M | 100% |
| Ohio | 196 | 9.2M | 2.1 | $5.1M | 32.6% |
| Maryland | 108 | 4.7M | 2.3 | $10.7M | 49% |
| Pennsylvania | 185 | 10.3M | 1.8 | $9.73M | 35% (medical) |
| Illinois | 264 | 10.4M | 2.1 | $7.42M | 30% |
| Connecticut | 72 | 2.9M | 2.5 | $4.03M | 20% |
Pennsylvania's 1.8 stores per 100K is adequate for a medical program where registered patients know where to go. It would be insufficient for adult-use. The $9.73M per-store revenue reflects high-transaction-value medical retail combined with 35% capture of a $5.15B market.
The Border Problem
Pennsylvania is encircled. New Jersey launched April 2022, New York December 2022, Maryland July 2023, Delaware 2025, Ohio August 2024. West Virginia remains medical-only.
The Philadelphia metro (6.2 million adults) is 10–30 minutes from New Jersey dispensaries at $8.80/g all-in — no medical card required. Governor Shapiro stated in February 2025 that cannabis company CEOs in New Jersey, Maryland, and New York told him 60% of their customers are Pennsylvanians. The Pittsburgh metro (2.3 million adults) sits 60–90 minutes from Ohio's border dispensaries at $7.39/g. The border bleed is not theoretical — it is structural, permanent, and growing as neighboring markets mature and price-compress.
Home Cultivation
Pennsylvania prohibits home cultivation for both medical patients and personal use. Home cultivation economics produce fewer than 5% participation even where freely permitted — the prohibition has no measurable effect on Pennsylvania's 65% black market share. That share is driven by the absence of adult-use legalization and five neighboring adult-use markets, not by patients growing in their basements.
What the CHS Literature Missed
Pennsylvania produces two of the most precise CHS framings in this dataset — from the state's own academic medical establishment.
Penn State Medicine testimony to the PA House Health Committee (November 2023): Dr. Kent Vrana, PhD, FAAAS — Chair of Pharmacology at Penn State College of Medicine and Director of Pennsylvania's designated Medical Marijuana Academic Clinical Research Center — submitted written testimony to the House Health Committee on cannabis legalization. On CHS, Dr. Vrana described it as "a well-documented medical condition in which selected individuals experience uncontrolled vomiting," linked to THC concentration and frequency of use. Pennsylvania's own state-designated marijuana research director — testifying on the public health considerations of legalization — did not cite a prevalence figure. He used the phrase "selected individuals."
Pennsylvania's $9.05 billion in cumulative sales and seven years of continuous per-patient consumption growth provide the behavioral falsification. The state's academic pharmacology director and largest hospital system both frame CHS as a condition affecting a defined subset. Neither source supports a 17–33% population-level prevalence claim.
The Legislative Failure
Key timeline:
- 2023: Bipartisan SB 846 (Laughlin-Street, private retail) referred to committee, dies without a vote
- May 7, 2025: House passes HB 1200 (102–101), state-run stores model
- May 13, 2025: Senate Law & Justice Committee defeats HB 1200, 7–3
- July 2025: Bipartisan SB 120 and HB 20 introduced (private retail); neither receives a hearing
- February 2026: Governor Shapiro's budget projects $729M first-year revenue; Senate noncommittal
The stalemate is structural: House Democrats want state-run stores; Senate Republicans want private retail. Both support legalization conceptually. Neither will move. Every month of deadlock costs Pennsylvania an estimated $280M+ in foregone legal sales while border state dispensaries fill the gap.
The Bottom Line
Pennsylvania's medical program is the strongest in the country by capture rate. Seven consecutive years of growth, 49% price compression, per-patient consumption that validates the 1.0 g/day framework, and 35% capture from a registration-required medical framework — all reflect sound policy execution. The 1.7% effective consumer tax burden is the lowest in the dataset. The program design is not the problem.
The $3.35 billion leaving Pennsylvania annually for black markets and five neighboring adult-use states is a legislative problem. The medical program will keep performing well regardless of what the Senate does. The question is whether the border bleed — now drawing from New Jersey, New York, Maryland, Delaware, and Ohio simultaneously — calcifies into permanent consumer habits before Harrisburg resolves a dispute over whether cannabis should be sold by the state or by private businesses.
This analysis applies the Dan K Reports Cannabis Market Framework. For methodology, assumptions, and the complete state-by-state comparison, see the framework documentation.